# Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis

> **NCT02364986** · PHASE1 · UNKNOWN · sponsor: **PD Dr. Marcus Müller** · enrollment: 50 (estimated)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Rebif®
- **DRUG:** Avonex

## Key facts

- **NCT ID:** NCT02364986
- **Lead sponsor:** PD Dr. Marcus Müller
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2016-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364986, "Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02364986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*